Human papillomavirus virus (HPV) is extremely common, with up to 80% of the world’s population likely infected at some point in their lives. Many people do not show any symptoms and the majority of cases go away without treatment. HPV infection is associated with cervical cancer and increases the risk of mouth and throat cancer. Recent studies have also associated HPV infection with increased risk of cardiovascular disease (CVD). Although HPV vaccinations are available, global vaccination rates are low despite the cancer risk.
In a recent study, infection with high-risk strains of HPV increased the risk of CVD, especially among women with obesity or other cardiovascular risk factors. These studies took place over several years with over 63,000 women that initially had no heart trouble. Factors including age, education, BMI, exercise and smoking habits were noted. Women with high-risk HPV were 22% more likely to develop CVD than uninfected women. This rate further increased in women with obesity or metabolic syndrome in addition to high-risk HPV. Further exploration is needed to determine factors that link high-risk HPV and CVD. Additional studies could determine if the vaccine strategies to reduce high-risk HPV infection for cancer prevention may help reduce the risk of CVD.
For more information:
https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.118.313779
Enzo Life Sciences provides a wide range of products for all your
Genomics and
In situ Hybridization research needs. Our platforms provide a wide range of
ISH virus detection tools including our PATHO-GENE® HPV Detection Assays and Specific Probes. We offer HPV Probes and typing assays for sensitive detection of pathogen-expressed genes from fresh or FFPE tissue sections.